Longevity Global Events Coming Up

#1

627xauto

Upcoming Events

You can see our global calendar of longevity events here.
Dec 16th
NeuroAge Test Q&A: Everything You Need to Know

​Join NeuroAge’s CEO, Dr. Christin Glorioso, to learn more about the NeuroAge Test and its new features.

Virtual (Register)
Jan 13th, 2026
Bits in Bio JPM Reception

Come meet with old and new friends at the Bits in Bio Reception happening during JPM Healthcare Week in San Francisco.

San Francisco, CA (Register)
Jan 15th-18th, 2026
Silicon Valley Applied Longevity Translation Symposium and Retreat

One day symposium at Stanford followed by a two day retreat directly following JP Morgan week in SF. Come to one or both.
The retreat is two days in half-moon bay and includes full body MRI, brain aging testing with NeuroAge, a sleep study, microbiome testing, and >1000 diagnostic tests.

Stanford, CA (Register)

561xauto

Mar 10th-12th, 2026
Intrinsic Capacity, Frailty and Sarcopenia Research Conference (ICFSR 2026)

This event brings together researchers, clinicians, and innovators to explore interventions that prevent frailty, preserve physical function, and delay dependency—through nutrition, exercise, geroscience-guided therapies, and other approaches…

Washington, DC (Register)
Mar 11-12th, 2026
Longevity Innovation Forum

At the 1st Annual Longevity Innovation Forum, we’re bringing together the builders of the longevity revolution — entrepreneurs, scientists, investors, and strategists transforming longevity from aspiration into industry.

San Diego, CA (Register)
526.3199999999999xauto
April 21st-25th, 2027
Longevity Global Retreat 2027

Resort in Costa Rica (Info/Save the Date)

#2

All of this is great, and it always seems like there is some new groundbreaking therapy to increase lifespan radically. However, they all seem to fizzle out after a deeper investigation. One of these days, I hope a reproducible game-changer is found! They all sound good on paper, but where’s the beef?

#3

That’s just the nature of the game. It has to succeed in a phase 3 trial or similar study.

#4

And I will add, Karl Pfleger in his talk (and who follows and invests heavily in the Longevity biotech field) thinks there will likely be 3 or more approved drugs in the next 5 to 10 years (given historical success rates of drugs in phase 3 clinical trials… something like 30% succeed), so the future looks pretty good. In fact, with SS-31 already FDA approved, we may already have one…

PXL_20251209_224127961
PXL_20251209_2241279613188×1809 462 KB

1 Like
#5

Technically are they going to be different from rapamycin? Will there be a measurable effect for N=1, where unlike rapamycin, you will know whether it works for you? If there is a measurable effect for rapa N=1 that I don’t remember, that would be interesting too.

#6

No - we still don’t have a good way to measure “aging” at a consumer level, so can’t measure drugs that impact it.

But these are drugs targeting specific pathways that are well documented as being key drivers of one of the hallmarks of aging…

#7

We’re relying on biohackers and others to try and report anecdotes then. If they’re FDA approved it helps to inform safety to some extent, at least.

1 Like